An Efficient Method to Generate Monoclonal Antibodies from Human B Cells
- 12 December 2018
- book chapter
- protocol
- Published by Springer Science and Business Media LLC
- Vol. 1904, 109-145
- https://doi.org/10.1007/978-1-4939-8958-4_5
Abstract
In the age of personalized medicine, an efficient method to generate monoclonal antibodies (mAbs) is essential for biomedical and immunotherapeutic research. Numerous aspects of basic B-cell biology can be studied at the monoclonal level, including B-cell development, antibody responses to infection or vaccination, and autoimmune responses. Single-cell B-cell receptor cloning allows for the rapid generation of antigen-specific mAbs in a matter of several weeks. In this chapter, we provide an efficient method to generate mAbs from peripheral blood plasmablasts and memory B cells induced by infection and vaccination. Additionally, we provide a protocol on how to optimize single-cell B-cell sorting for both single-cell B-cell receptor cloning and single-cell RNA-sequencing, for the application of studying B-cell specificity and function (spec-seq). This protocol can be easily adapted for other B-cell populations, B cells in tissues, and B cells from other organisms.Keywords
This publication has 42 references indexed in Scilit:
- Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive AntibodiesCell, 2018
- Antibody-Based Strategies to Prevent and Treat InfluenzaFrontiers in Immunology, 2015
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsThe New England Journal of Medicine, 2015
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1Science, 2010
- Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine TargetScience, 2009
- Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune GlobulinThe New England Journal of Medicine, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal TransplantationThe New England Journal of Medicine, 1998